Clinical Trial Update: Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating an extended-release combination tablet of niacin, laropiprant, and simvastatin in individuals with primary hypercholesterolemia or mi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Laropiprant (laropiprant)
• Niacin Extended-Release (nicotinic acid)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Status: TERMINATED | Results posted: 2016-06-21